Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1993 Nov;68(5):898–908. doi: 10.1038/bjc.1993.452

Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.

G J Schuurhuis 1, T H van Heijningen 1, A Cervantes 1, H M Pinedo 1, J H de Lange 1, H G Keizer 1, H J Broxterman 1, J P Baak 1, J Lankelma 1
PMCID: PMC1968747  PMID: 8105865

Abstract

Doxorubicin accumulation defects in multidrug resistant tumour cells are generally small in comparison to the resistance factors. Therefore additional mechanisms must be operative. In this paper we show by a quantitative approach that doxorubicin resistance in several P-glycoprotein-positive non-small cell lung cancer and breast cancer multidrug resistant cell lines can be explained by a summation of accumulation defect and alterations in the efficacy of the drug once present in the cell. This alteration of efficacy was partly due to changes in intracellular drug localisation, characterised by decreased nuclear/cytoplasmic doxorubicin fluorescence ratios (N/C-ratios). N/C-ratios were 2.8-3.6 in sensitive cells, 0.1-0.4 in cells with high (> 70-fold) levels of doxorubicin resistance and 1.2 and 1.9 in cells with low or intermediate (7.5 and 24-fold, respectively) levels of doxorubicin resistance. The change of drug efficacy was reflected by an increase in the total amount of doxorubicin present in the cell at equitoxic (IC50) concentrations. N/C ratios in highly resistant P-glycoprotein-containing cells could be increased with the resistance modifier verapamil to values of 1.3-2.7, a process that was paralleled by a decrease of the cellular doxorubicin amounts present at IC50. At the low to moderate residual levels of resistance, obtained with different concentrations of verapamil, a linear relationship between IC50 and cellular doxorubicin amounts determined at IC50 was found. This shows that at this stage of residual resistance, extra reversal by verapamil should be explained by further increase of drug efficacy rather than by increase of cellular drug accumulation. A similar relationship was found for P-glycoprotein-negative MDR cells with low levels of resistance. Since in these cells N/C ratios could not be altered, verapamil-induced decrease of IC50 must be due to increased drug efficacy by action on as yet unidentified targets. Although the IC50 of sensitive human cells cannot be reached with resistance modifiers, when using these relationships it can be shown by extrapolation that cellular and nuclear doxorubicin amounts at IC50 at complete reversal of resistance were the same as in sensitive cells. It is concluded that doxorubicin resistance factors for multidrug resistant cells can for a large part, and in the case of P-glycoprotein-containing cells probably fully, be accounted for by decreased amounts of drug at nuclear targets, which in turn is characterised by two processes only: decreased cellular accumulation and a shift in the ratio nuclear drug/cytoplasmic drug.

Full text

PDF
898

Images in this article

903Figure 7
on p.903
905Figure 9
on p.905

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baas F., Jongsma A. P., Broxterman H. J., Arceci R. J., Housman D., Scheffer G. L., Riethorst A., van Groenigen M., Nieuwint A. W., Joenje H. Non-P-glycoprotein mediated mechanism for multidrug resistance precedes P-glycoprotein expression during in vitro selection for doxorubicin resistance in a human lung cancer cell line. Cancer Res. 1990 Sep 1;50(17):5392–5398. [PubMed] [Google Scholar]
  2. Batist G., Schecter R., Woo A., Greene D., Lehnert S. Glutathione depletion in human and in rat multi-drug resistant breast cancer cell lines. Biochem Pharmacol. 1991 Feb 15;41(4):631–635. doi: 10.1016/0006-2952(91)90638-l. [DOI] [PubMed] [Google Scholar]
  3. Batist G., Tulpule A., Sinha B. K., Katki A. G., Myers C. E., Cowan K. H. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986 Nov 25;261(33):15544–15549. [PubMed] [Google Scholar]
  4. Beck W. T. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J Natl Cancer Inst. 1989 Nov 15;81(22):1683–1685. doi: 10.1093/jnci/81.22.1683. [DOI] [PubMed] [Google Scholar]
  5. Bellamy W. T., Dalton W. S., Kailey J. M., Gleason M. C., McCloskey T. M., Dorr R. T., Alberts D. S. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res. 1988 Nov 15;48(22):6365–6370. [PubMed] [Google Scholar]
  6. Bellamy W. T., Dorr R. T., Dalton W. S., Alberts D. S. Direct relation of DNA lesions in multidrug-resistant human myeloma cells to intracellular doxorubicin concentration. Cancer Res. 1988 Nov 15;48(22):6360–6364. [PubMed] [Google Scholar]
  7. Bradley G., Juranka P. F., Ling V. Mechanism of multidrug resistance. Biochim Biophys Acta. 1988 Aug 3;948(1):87–128. doi: 10.1016/0304-419x(88)90006-6. [DOI] [PubMed] [Google Scholar]
  8. Broxterman H. J., Pinedo H. M., Kuiper C. M., Kaptein L. C., Schuurhuis G. J., Lankelma J. Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells. FASEB J. 1988 Apr;2(7):2278–2282. doi: 10.1096/fasebj.2.7.3350243. [DOI] [PubMed] [Google Scholar]
  9. Cano-Gauci D. F., Riordan J. R. Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation. Biochem Pharmacol. 1987 Jul 1;36(13):2115–2123. doi: 10.1016/0006-2952(87)90139-0. [DOI] [PubMed] [Google Scholar]
  10. Cole S. P., Chanda E. R., Dicke F. P., Gerlach J. H., Mirski S. E. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 1991 Jul 1;51(13):3345–3352. [PubMed] [Google Scholar]
  11. Cole S. P., Downes H. F., Slovak M. L. Effect of calcium antagonists on the chemosensitivity of two multidrug-resistant human tumour cell lines which do not overexpress P-glycoprotein. Br J Cancer. 1989 Jan;59(1):42–46. doi: 10.1038/bjc.1989.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Coley H. M., Workman P., Twentyman P. R. Retention of activity by selected anthracyclines in a multidrug resistant human large cell lung carcinoma line without P-glycoprotein hyperexpression. Br J Cancer. 1991 Mar;63(3):351–357. doi: 10.1038/bjc.1991.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Cowan K. H., Batist G., Tulpule A., Sinha B. K., Myers C. E. Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci U S A. 1986 Dec;83(24):9328–9332. doi: 10.1073/pnas.83.24.9328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Danks M. K., Yalowich J. C., Beck W. T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 1987 Mar 1;47(5):1297–1301. [PubMed] [Google Scholar]
  15. Fairchild C. R., Ivy S. P., Kao-Shan C. S., Whang-Peng J., Rosen N., Israel M. A., Melera P. W., Cowan K. H., Goldsmith M. E. Isolation of amplified and overexpressed DNA sequences from adriamycin-resistant human breast cancer cells. Cancer Res. 1987 Oct 1;47(19):5141–5148. [PubMed] [Google Scholar]
  16. Ford J. M., Prozialeck W. C., Hait W. N. Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol. 1989 Jan;35(1):105–115. [PubMed] [Google Scholar]
  17. Gervasoni J. E., Jr, Fields S. Z., Krishna S., Baker M. A., Rosado M., Thuraisamy K., Hindenburg A. A., Taub R. N. Subcellular distribution of daunorubicin in P-glycoprotein-positive and -negative drug-resistant cell lines using laser-assisted confocal microscopy. Cancer Res. 1991 Sep 15;51(18):4955–4963. [PubMed] [Google Scholar]
  18. Gigli M., Rasoanaivo T. W., Millot J. M., Jeannesson P., Rizzo V., Jardillier J. C., Arcamone F., Manfait M. Correlation between growth inhibition and intranuclear doxorubicin and 4'-deoxy-4'-iododoxorubicin quantitated in living K562 cells by microspectrofluorometry. Cancer Res. 1989 Feb 1;49(3):560–564. [PubMed] [Google Scholar]
  19. Haber M., Norris M. D., Kavallaris M., Bell D. R., Davey R. A., White L., Stewart B. W. Atypical multidrug resistance in a therapy-induced drug-resistant human leukemia cell line (LALW-2): resistance to Vinca alkaloids independent of P-glycoprotein. Cancer Res. 1989 Oct 1;49(19):5281–5287. [PubMed] [Google Scholar]
  20. Harker W. G., Slade D. L., Dalton W. S., Meltzer P. S., Trent J. M. Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression. Cancer Res. 1989 Aug 15;49(16):4542–4549. [PubMed] [Google Scholar]
  21. Hindenburg A. A., Baker M. A., Gleyzer E., Stewart V. J., Case N., Taub R. N. Effect of verapamil and other agents on the distribution of anthracyclines and on reversal of drug resistance. Cancer Res. 1987 Mar 1;47(5):1421–1425. [PubMed] [Google Scholar]
  22. Hindenburg A. A., Gervasoni J. E., Jr, Krishna S., Stewart V. J., Rosado M., Lutzky J., Bhalla K., Baker M. A., Taub R. N. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res. 1989 Aug 15;49(16):4607–4614. [PubMed] [Google Scholar]
  23. Keizer H. G., Joenje H. Increased cytosolic pH in multidrug-resistant human lung tumor cells: effect of verapamil. J Natl Cancer Inst. 1989 May 3;81(9):706–709. doi: 10.1093/jnci/81.9.706. [DOI] [PubMed] [Google Scholar]
  24. Keizer H. G., Schuurhuis G. J., Broxterman H. J., Lankelma J., Schoonen W. G., van Rijn J., Pinedo H. M., Joenje H. Correlation of multidrug resistance with decreased drug accumulation, altered subcellular drug distribution, and increased P-glycoprotein expression in cultured SW-1573 human lung tumor cells. Cancer Res. 1989 Jun 1;49(11):2988–2993. [PubMed] [Google Scholar]
  25. McGrath T., Center M. S. Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res. 1988 Jul 15;48(14):3959–3963. [PubMed] [Google Scholar]
  26. McGrath T., Marquardt D., Center M. S. Multiple mechanisms of adriamycin resistance in the human leukemia cell line CCRF-CEM. Biochem Pharmacol. 1989 Feb 1;38(3):497–501. doi: 10.1016/0006-2952(89)90390-0. [DOI] [PubMed] [Google Scholar]
  27. Moscow J. A., Townsend A. J., Cowan K. H. Elevation of pi class glutathione S-transferase activity in human breast cancer cells by transfection of the GST pi gene and its effect on sensitivity to toxins. Mol Pharmacol. 1989 Jul;36(1):22–28. [PubMed] [Google Scholar]
  28. Politi P. M., Arnold S. T., Felsted R. L., Sinha B. K. P-glycoprotein-independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Mol Pharmacol. 1990 Jun;37(6):790–796. [PubMed] [Google Scholar]
  29. Scheper R. J., Bulte J. W., Brakkee J. G., Quak J. J., van der Schoot E., Balm A. J., Meijer C. J., Broxterman H. J., Kuiper C. M., Lankelma J. Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer. 1988 Sep 15;42(3):389–394. doi: 10.1002/ijc.2910420314. [DOI] [PubMed] [Google Scholar]
  30. Schuurhuis G. J., Broxterman H. J., Cervantes A., van Heijningen T. H., de Lange J. H., Baak J. P., Pinedo H. M., Lankelma J. Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells. J Natl Cancer Inst. 1989 Dec 20;81(24):1887–1892. doi: 10.1093/jnci/81.24.1887. [DOI] [PubMed] [Google Scholar]
  31. Schuurhuis G. J., Broxterman H. J., Pinedo H. M., van Heijningen T. H., van Kalken C. K., Vermorken J. B., Spoelstra E. C., Lankelma J. The polyoxyethylene castor oil Cremophor EL modifies multidrug resistance. Br J Cancer. 1990 Oct;62(4):591–594. doi: 10.1038/bjc.1990.335. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Schuurhuis G. J., Broxterman H. J., de Lange J. H., Pinedo H. M., van Heijningen T. H., Kuiper C. M., Scheffer G. L., Scheper R. J., van Kalken C. K., Baak J. P. Early multidrug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br J Cancer. 1991 Nov;64(5):857–861. doi: 10.1038/bjc.1991.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Schuurhuis G. J., Broxterman H. J., van der Hoeven J. J., Pinedo H. M., Lankelma J. Potentiation of doxorubicin cytotoxicity by the calcium antagonist bepridil in anthracycline-resistant and -sensitive cell lines. A comparison with verapamil. Cancer Chemother Pharmacol. 1987;20(4):285–290. doi: 10.1007/BF00262578. [DOI] [PubMed] [Google Scholar]
  34. Schuurhuis G. J., Pinedo H. M., Broxterman H. J., van Kalken C. K., Kuiper C. M., Lankelma J. Differential sensitivity of multi-drug-resistant and -sensitive cells to resistance-modifying agents and the relation with reversal of anthracycline resistance. Int J Cancer. 1990 Aug 15;46(2):330–336. doi: 10.1002/ijc.2910460232. [DOI] [PubMed] [Google Scholar]
  35. Seeber S., Loth H., Crooke S. T. Comparative nuclear and cellular incorporation of daunorubicin, doxorubicin, carminomycin, marcellomycin, aclacinomycin A and AD 32 in daunorubicin-sensitive and -resistant Ehrlich ascites in vitro. J Cancer Res Clin Oncol. 1980;98(2):109–118. doi: 10.1007/BF00405955. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sehested M., Skovsgaard T., van Deurs B., Winther-Nielsen H. Increased plasma membrane traffic in daunorubicin resistant P388 leukaemic cells. Effect of daunorubicin and verapamil. Br J Cancer. 1987 Dec;56(6):747–751. doi: 10.1038/bjc.1987.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Sinha B. K., Katki A. G., Batist G., Cowan K. H., Myers C. E. Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry. 1987 Jun 30;26(13):3776–3781. doi: 10.1021/bi00387a006. [DOI] [PubMed] [Google Scholar]
  38. Sinha B. K., Mimnaugh E. G. Free radicals and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic Biol Med. 1990;8(6):567–581. doi: 10.1016/0891-5849(90)90155-c. [DOI] [PubMed] [Google Scholar]
  39. Slapak C. A., Daniel J. C., Levy S. B. Sequential emergence of distinct resistance phenotypes in murine erythroleukemia cells under adriamycin selection: decreased anthracycline uptake precedes increased P-glycoprotein expression. Cancer Res. 1990 Dec 15;50(24):7895–7901. [PubMed] [Google Scholar]
  40. Slapak C. A., Lecerf J. M., Daniel J. C., Levy S. B. Energy-dependent accumulation of daunorubicin into subcellular compartments of human leukemia cells and cytoplasts. J Biol Chem. 1992 May 25;267(15):10638–10644. [PubMed] [Google Scholar]
  41. Slovak M. L., Hoeltge G. A., Dalton W. S., Trent J. M. Pharmacological and biological evidence for differing mechanisms of doxorubicin resistance in two human tumor cell lines. Cancer Res. 1988 May 15;48(10):2793–2797. [PubMed] [Google Scholar]
  42. Tarasiuk J., Frézard F., Garnier-Suillerot A., Gattegno L. Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. Biochim Biophys Acta. 1989 Sep 19;1013(2):109–117. doi: 10.1016/0167-4889(89)90038-4. [DOI] [PubMed] [Google Scholar]
  43. Taylor C. W., Dalton W. S., Parrish P. R., Gleason M. C., Bellamy W. T., Thompson F. H., Roe D. J., Trent J. M. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. Br J Cancer. 1991 Jun;63(6):923–929. doi: 10.1038/bjc.1991.202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Thiebaut F., Currier S. J., Whitaker J., Haugland R. P., Gottesman M. M., Pastan I., Willingham M. C. Activity of the multidrug transporter results in alkalinization of the cytosol: measurement of cytosolic pH by microinjection of a pH-sensitive dye. J Histochem Cytochem. 1990 May;38(5):685–690. doi: 10.1177/38.5.1692055. [DOI] [PubMed] [Google Scholar]
  45. Willingham M. C., Cornwell M. M., Cardarelli C. O., Gottesman M. M., Pastan I. Single cell analysis of daunomycin uptake and efflux in multidrug-resistant and -sensitive KB cells: effects of verapamil and other drugs. Cancer Res. 1986 Nov;46(11):5941–5946. [PubMed] [Google Scholar]
  46. Willingham M. C., Richert N. D., Cornwell M. M., Tsuruo T., Hamada H., Gottesman M. M., Pastan I. H. Immunocytochemical localization of P170 at the plasma membrane of multidrug-resistant human cells. J Histochem Cytochem. 1987 Dec;35(12):1451–1456. doi: 10.1177/35.12.2890686. [DOI] [PubMed] [Google Scholar]
  47. Yusa K., Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 1989 Sep 15;49(18):5002–5006. [PubMed] [Google Scholar]
  48. Zamora J. M., Pearce H. L., Beck W. T. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol. 1988 Apr;33(4):454–462. [PubMed] [Google Scholar]
  49. de Lange J. H., Schipper N. W., Schuurhuis G. J., ten Kate T. K., van Heijningen T. H., Pinedo H. M., Lankelma J., Baak J. P. Quantification by laser scan microscopy of intracellular doxorubicin distribution. Cytometry. 1992;13(6):571–576. doi: 10.1002/cyto.990130604. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES